



## Personal information

First name(s) / Surname(s) **Leonardo Michele Fabbri**  
*H Index October 2019: 113 Google Scholar; 95 Scopus*

Address **Viale Verdi, 59 - 41121, Modena, Italy**

Telephone **+39 059-235802; +39 0532291297**

Fax **+39 059 235802; +39 0532 291297**

Mobile **+39 348-9902706; +39 348-9934593**

E-mail **[leonardo.fabbri20@gmail.com](mailto:leonardo.fabbri20@gmail.com)**

Nationality **Italian**

Date of birth **June 8, 1947**

Gender **Male**

**Occupational field** **Medical Doctor**

## Work experience

**University of Ferrara**  
From 1 October 2017 to date  
Eminent Scholar of Internal and Respiratory Medicine

**University of Gothenburg**  
From 1 May 2017 to date  
Visiting Professor of Internal and Respiratory Medicine

**Name and address of employer** **University of Modena and Reggio Emilia – Modena Hospital (-2016)**  
**Via Università 5 - 41121 Modena – Italy**

**From 1 November 2015 to 31 October 2016**  
**Professor of Internal Medicine**  
**Director of Internal Medicine**  
**Director of the Department of Internal Medicine**

**Academic positions held** **From 1 March 2000 to 31 October 2015**  
**Professor of Respiratory Diseases (2000-)**  
**Director of Respiratory Diseases (2000-)**  
**Director of Medical Oncology (2013-2015)**  
**Director of the Department of Oncology, Hematology and Respiratory Diseases (2010-2015)**  
**Professor and Director of Internal Medicine (2016)**

**Teaching positions held** **From 2003 to 2007 and from 2008 to 2010**  
**Director of the Post-Graduate School of Respiratory Diseases**  
**University – Hospital of Modena e Reggio Emilia**

**From 2003 to 2007**  
 Director, School of Physiotherapy  
 University – Hospital of Modena e Reggio Emilia

**From 1992 to 2000**  
 Associate Professor of Respiratory Diseases  
 Director of the Research Centre for Asthma and COPD (1993-2000)  
 University of Ferrara  
 Via Savonarola, 9 - 44121 FERRARA – Italy

**From 1991 to 1992**  
 Assistant Professor of Medicine (Ricercatore), Respiratory Diseases  
 University – Hospital of Ferrara

**From 1981 to 1991**  
 Assistant Professor of Medicine (Ricercatore), Occupational Medicine  
 Director of the Laboratory of Respiratory Physiology (1983-1991)  
 University – Hospital of Padova  
 Via 8 Febbraio 1848 – 35100 Padova - Italy

**Education and training**

<b>Dates</b>	<b>1961-1966</b>
<b>Title of qualification awarded</b>	High School I. Nievo-Padova Scientific Maturity
<b>Post-Graduate Training</b>	<p><b>1966-1972</b>          Degree in Medicine and Surgery, 110/110 summa cum laude, University of Padova - Italy</p> <p>Board in Occupational Medicine, 1975, University of Padua, 70/70 summa cum laude          Board in Respiratory Diseases, 1978, University of Bologna, 70/70 summa cum laude</p> <p><b>1980 – 1981</b>          Visiting Scientist          Department of Respiratory Diseases          Tulane University, New Orleans, USA, School of Medicine</p> <p><b>1981 – 1983</b>          Visiting Scientist          University of California, San Francisco, Cardiovascular Research Institute</p>

**Personal skills and competences**

Mother tongue(s) **Italian**

Other language(s) **English**

Self-assessment  
 European level (\*)

**Language**

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
excellent	excellent	excellent	excellent	excellent

(\*) [Common European Framework of Reference for Languages](#)

**Editorial assignments****Associate Editor for :**

- American Journal Respiratory and Critical Care Medicine, 1999-2009
- American Journal Respiratory and Critical Care Medicine, 2015 – to date
- European Respiratory Journal, 2004 -2018
- Lancet Respiratory Medicine, 2013 - to date
- Canadian Respiratory Journal, 2016-2019
- Journal of COPD, 2004 - to date
- Respiratory Research, 2005 - to date
- European Journal of Clinical Investigation 2010 - 2019
- Italian Journal of Internal Medicine, 2010 - to date
- PLOS-ONE, september 2013 – 2019

**Reviewer of Research Projects****For:**

European Union almost yearly from 2005  
Framework Program 7  
Innovative Medicine Initiative  
German Center for Lung Research, 2011  
Spanish Clinical Research Network- Instituto de Salud Carlos III - Ministerio de Ciencia  
The Swedish Foundation for Strategic Research  
Slovenian Research Agency  
Research Council K.U.Leuven, Belgium  
Cineca – referee scientific products (VQR) for the Italian Ministry of University  
Cineca – referee research projects (FIRB) for the Italian Ministry of University  
French Ministry of Research, 2015

**Role in Scientific Societies**

Presidential cycle - European Respiratory Society (ERS) 2005-2009  
President - European Respiratory Society (ERS) 2007-2008  
Member of the International Committee for the "Global Initiative on Asthma", sponsored by the NHLBI and the WHO, 1990-1997  
Member of the International Committee Committee, International Committee for the "Global Strategy on COPD", sponsored by the NHLBI and the WHO, 1997-2017

**Honors**

**Honorary Lecturer, Michael Newhouse Lectureship, "Occupational Asthma, 21 February 1994 aster University, Hamilton, Ontario, Canada**  
Honorary Member, Austrian Society of Hospital Pulmonology, 1998  
Elected Member, Fleischner Society, 1998-  
Honorary member of the *Collegii Regalis Modicorum Londinenses*, (Royal College of Physicians) April 2000-  
*Honorary Lecturer "Jeff Drazen's Lecture"*, Harvard School of Public Health – Massachusetts General Hospital, Boston 10-11 October 2002  
Honorary Member of the Italia Association of Hospital Internists (FADOI)  
Honorary Citizen of Santa Sofia (FC), City of origin of his Family  
Giant in Respiratory Medicine, American College of Chest Physicians, 2016  
Margareth Turner Warwick Honorary Lecturer, Imperial College, London, 2017  
Eminent Scholar, University of Ferrara, Italy, 2016

**Principal or co-principal Investigator of competitive research Grants**

Italian Ministry of University and Research, continuously from 1980-1995  
European Community, 2 Grants on Severe Asthma  
Italian Ministry of Health, 5 Grants of 1) € 700,000, 2005, Principal Investigator, Role of pro-calcitonin in prescribing antibiotics for AECOPD, 2) € 750,000, 2010, Principal Investigator, Assessment of severity of patients with multimorbidity 3) € 1,000,000, 2006, co-principal investigator, for the Comparison between guideline recommended treatment of mild asthma with regular BDP + prn albuterol versus placebo and prn ICS + albuterol; 4) € 1,000,000, 2011, co-principal investigator, for the Comparison between guideline recommended treatment of moderate asthma with regular budesonide/formoterol + prn albuterol versus regular placebo + prn budesonide/formoterol; 5) € 3,000,000, 2007, Co-principal Investigator for the assessment of inhaled ICS containing combinations versus non-ICS combinations in the 1 year follow-up treatment of COPD patients discharged after an AECOPD

**PUBLICATIONS (> 550)** To see the work, go to the website of the National Library of Medicine <http://www.ncbi.nlm.nih.gov/pubmed> typing into the "Search for": Fabbri L an Fabbri LM)

**Leonardo M. Fabbri, MD, FERS**

### Ten most relevant original publications

Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. *Lancet Respir Med*. 2019 Mar 12. pii: S2213-2600(19)30049-9. doi: 10.1016/S2213-2600(19)30049-9. [Epub ahead of print] PubMed PMID: 30876830.

Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. *Lancet Respir Med*. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. Erratum in: *Lancet Respir Med*. 2018 Oct 4;:. PubMed PMID: 30232048.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet*. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: *Lancet*. 2018 Feb 26;:. PubMed PMID: 29429593.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicenter randomised controlled trial. *Lancet*. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. PubMed PMID: 25684586.

Papi A, Marku B, Scichilone N, Maestrelli P, Paggiaro P, Saetta M, Nava S, Folletti I, Bertorelli G, Bertacco S, Contoli M, Plebani M, Barbaro MPF, Spanevello A, Aliani M, Pannacci M, Morelli P, Begh  B, Fabbri LM; AIFASMA Study Group. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. *Lancet Respir Med*. 2015 Feb;3(2):109-119. doi: 10.1016/S2213-2600(14)70266-8. Epub 2014 Dec 4. PubMed PMID: 25481378.

Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. *Lancet Respir Med*. 2013 Mar;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2. Epub 2013 Mar 4. PubMed PMID: 24321801.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van M lken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med*. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378. PubMed PMID: 21428765.

Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. *Lancet*. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6. PubMed PMID: 19716961.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: *Lancet*. 2010 Oct 2;376(9747):1146. PubMed PMID: 19716960.

Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. *N Engl J Med*. 2007 May 17;356(20):2040-52. PubMed PMID: 17507703.

### Ten most relevant editorial/reviews

Fabbri LM, Beghe B, and Papi A. Blood eosinophils for the management of COPD patients? *Lancet Respir Med*. 2018, on line 17 October 2018

Fabbri LM, Roversi S, Beghé B. Triple therapy for symptomatic patients with COPD. *Lancet*. 2017 May 13;389(10082):1864-1865. doi: 10.1016/S0140-6736(17)30567-6. Epub 2017 Apr 4. PubMed PMID: 28385354.

Papi A, Fabbri LM. Management of patients with early mild asthma and infrequent symptoms. *Lancet*. 2017 Jan 14;389(10065):129-130. doi: 10.1016/S0140-6736(16)32111-0. Epub 2016 Nov 30. PubMed PMID: 27912984.

Fabbri LM. Symptoms in Smokers with Preserved Pulmonary Function. *N Engl J Med*. 2016 Sep 1;375(9):897. doi: 10.1056/NEJMc1608235. PubMed PMID: 27579643.

Fabbri LM. Smoking, Not COPD, as the Disease. *N Engl J Med*. 2016 May 12;374(19):1885-6. doi: 10.1056/NEJMe1515508. PubMed PMID: 27168438.

Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. *Am J Respir Crit Care Med*. 2016 Dec 1;194(11):1319-1336. Review. PubMed PMID: 27589227

Fabbri LM. Benralizumab: for asthma, not yet for COPD. *Lancet Respir Med*. 2014 Nov;2(11):862-863. doi: 10.1016/S2213-2600(14)70225-5. Epub 2014 Oct 8. PubMed PMID: 25306558.

Fabbri LM, Beghé B, Yasothan U, Kirkpatrick P. Roflumilast. *Nat Rev Drug Discov*. 2010 Oct;9(10):761-2. doi: 10.1038/nrd3276. PubMed PMID: 20885403.

Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? *Lancet*. 2007 Sep 1;370(9589):797-9. PubMed PMID: 17765529.

Fabbri LM. Does mild persistent asthma require regular treatment? *N Engl J Med*. 2005 Apr 14;352(15):1589-91. PubMed PMID: 15829540.

### BOOKS FOR MEDICAL STUDENTS

Rugarli C. *Medicina Interna Sistemica*. VII, VIII e IX Edizione. Parte 1: Malattie dell' Apparato Respiratorio, A cura di LM Fabbri LM. EDRA-Masson, Milano, 2010 (VI Ed), 2015 (VII Edi), 2020 (VIII Edition, in preparation)

Fabbri LM e Marsico SA. *Trattato di Malattie Respiratorie*. Edises, Napoli, 2013

